Your Annual Industry Touchpoint to Maximize the Therapeutic Index of Your ADC

Accelerate Your Antibody-Drug Conjugate Pipeline to Become a Front-Line Treatment

Antibody-drug conjugates are receiving unrivaled attention across the biopharma sector. Fueled by Enhertu’s tumor-agnostic accelerated approval, practice changing combination results from Seagen and Astellas’ PADCEV, all alongside a frenzy of companies entering the field and billion-dollar partnerships and M&As from Pfizer, AbbVie, J&J, Merck, Genmab, Ipsen and beyond, ADCs have firmly positioned themselves at the forefront of oncology R&D and dealmaking.

Returning as industry’s definitive ADC forum from early discovery to late-phase manufacturing, the 15th World ADC San Diego is the world-leading, largest, and most comprehensive ADC-focused conference to maximize the therapeutic window of ADCs. Whether you have just ventured into the ADC space or are an ADC guru, you’ll leave this meeting with the insight and connections needed to overcome your challenges and make impactful strides in your work.

FULL EVENT GUIDE

brochure ss

Uniting over 1,200 ADC enthusiasts from field novices to long-standing KOLs including experts from Daiichi Sankyo, Pfizer, AbbVie, AstraZeneca, and ADC Therapeutics, World ADC San Diego is the annual community touchpoint to gain unparalleled knowledge across cutting-edge R&D, end-to-end development strategy, and global market trends to progress ADCs to new standard of care treatments in oncology and beyond.

Previous Attending Companies Include...

Cutting-Edge, End-to-End Scientific Content for All Stages of ADC Development

From new members to long-standing experts in the ADC field, our program has you covered:

Intro
23
24
25
26
27
28

Your 140+ World Class Speakers Include:

Ahsan Arozullah

Senior Vice President, Head of Oncology Development

Astellas Innovation Management LLC

Bilal Piperdi

Vice President, Clinical Development Oncology

Gilead Sciences

Ilaria Conti

Vice President, Global Early-Stage Clinical Development, Oncology

ADC Therapeutics

Mary Jane Hinrichs

Senior Vice President, Global Head of Early Development

Ipsen Pharma

Puja Sapra

Senior Vice President, Biologics Engineering & Oncology Targeted Discovery, Oncology R&D

AstraZeneca

Radhika Balasubramani

Director, Technical Product Steward, Antibody Drug Conjugates

Merck & Co

Ricardo Zwirtes

Executive Director, Global Clinical Lead

Daiichi Sankyo, Inc.

Scott Peterson

Head of ADC Discovery and Cancer Immunology

Pfizer

Proud to Partner With:

Lead Partner

bsp

Senior Partners

Ajinomoto-Bio-Pharma-Services (1)
Millipore Sigma
NJ Bio
ambrx
Simris
Singzyme

Partners

A&G Pharma
Abzena
Alloy Therapeutics
Asymbio CN
Axplora
Aureka Bio,
Beacon Targeted Therapeutics
catalent bio
catena_biosciences_logo
CHO Pharma
Cytiva
GeneQuantum Healthcare
glykos_finland_logo
Immunwork logo
intocell
InxMed Logo
Legochem Biosciences
Lonza
Natera_logo
Nona Biosciences
OmniAb
Piramal Pharma Solutions Logo (PRNewsfoto/Piramal Pharma Solutions)
Logo_PROVEO_Payoff-OK
Trinity_SafeBridgeRegulatoryLifeSciencesGroup_Iron_RGB
Samsung Biologics
Sartorius
SCIEX
Tempus
Valentia Analytical
vera
XDC The Bioconjugation Leader

Exhibitors

AlpaLifeBio
Altruist Bio
Aton Bio
Avis Bioservices
Biocytogen
Biopharmaspec
BOCSCI
haoyuan_chemexpress_co_ltd_logo
Creative Biolabs
Curia
Discovery LS
Exon Bio
gear
Halo Labs
Huida-Biotech-2048x676
IDT Australia
ILC Dover
Inabata -
Indena
kyon
Mabplex
Medicilon Logo
Olon
Promega -
sanyou bio
Symbiosis
Tanvex CMDO logo
TOT Biopharm

Event Partners

AppliedBioMath
TheraTechnologies
Valentia Analytical

About World ADC Series

The World ADC team ploughs its collective energy in to sourcing the insights you need. We investigate the most challenging problems facing the industry; source the leading experts who have game-changing solutions; and distil this into accessible formats of information exchange – for you. From globally leading conferences to webinars and industry reports, whatever the information you need, World ADC can offer you the insights you need to accelerate your ADC programs.

The value World ADC provides you is the power of insight and connections. Not artificial, and not short-lived. We nurture the right environments in which people can communicate problems and solutions; share novel data and forge networks across the industry that will make each of your endeavours more informed and more robust.

We share a common belief with the industry – that the potential of antibody drug conjugates is enormous. In the war against cancer, ADCs can be a game-changer and we know that the right insights and connections can sharpen the weapons that are in your arsenal.

Join us at the heart of the ADC community to improve your programmes and be part of the mission to develop better antibody drug conjugate drugs.

ADC SD Social Card (1)